Sotagliflozin, a dual SGLT1/2 inhibitor, increased hemoglobin levels in patients with type 2 diabetes and chronic kidney ...
U.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo® (vadadustat) for CKD Patients on Dialysis ...
The following is a summary of “Erythrocyte indices and response to hypoxia-inducible factor prolyl hydroxylase inhibitors in ...
A new study published in the journal of BMC Nephrology showed that the effectiveness of roxadustat is comparable at varying ...
Summary Although erythropoiesis-stimulating agents (ESAs) are the mainstay of anemia treatment, concomitant iron supplementation is often required. Patients with CKD are at risk for developing ...
AKI - the other main type of kidney disease - can be caused by dehydration, blood loss, urinary tract obstructions such as ...
“CSL has an outstanding track record over the long term,” said David Grace of the Australian Foundation Investment Company, which owns about A$629 million of the company’s shares and has been invested ...
Severe vivax malaria, once considered a relatively benign infection compared to its counterpart P. falciparum, has emerged as a significant health concern with severe and life-threatening ...
but as CKD progresses, "complications like high blood pressure, heart disease, anemia, nerve damage, and fluid retention can arise," says Nagata. "Without treatment, chronic kidney disease can ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback